LyP-1修飾負(fù)載核酸/藥物的靶向脂質(zhì)體
LyP-1 是一種環(huán)狀 9 個氨基酸的腫瘤的定位肽，在多種腫瘤相關(guān)細(xì)胞中，選擇性結(jié)合其 p32 receptor 蛋白。
LyP-1 (8?weeks) shows a remarkable reduction in plaque formation and plaque occupation rates in the LyP-1-treated grou

LyP-1修飾負(fù)載核酸/藥物的靶向脂質(zhì)體

【中文名稱】

腫瘤淋巴管歸巢肽LyP-1修飾負(fù)載核酸/藥物的靶向脂質(zhì)體

【英文名稱】

Targeted liposome coated withLyP-1

【純   度】

95%以上

【保存】

4℃保存

【規(guī)格】

50mg，10mg/ml

【產(chǎn)品特性】

LyP-1 是一種環(huán)狀 9 個氨基酸的腫瘤的定位肽，在多種腫瘤相關(guān)細(xì)胞中，選擇性結(jié)合其 p32 receptor 蛋白。

LyP-1 (8?weeks) shows a remarkable reduction in plaque formation and plaque occupation rates in the LyP-1-treated group. In addition, a higher apoptotic rate in macrophages released from hypoxic plaques is observed after the treatment of LyP-1when compared to control peptide^[1].
The LyP-1 peptide is labeled with a near-infrared fluorophore (Cy5.5) for optical imaging.
At days 3, 7, 14 and 21 after inoculation with 4T1 cells, tumor-bearing BALB/C mice is injected Cy5.5-LyP-1 (0.8 nmol) through the middle phalanges of the upper extremities of the tumor-bearing mice. The fluorescence intensities were 0.024, 0.038, 0.048 and 0.106×10⁶ photon/cm²/sec respectively at days 3, 7, 14 and 21 after tumor cell inoculation, which are 1.02, 1.63, 2.04, and 4.52-fold higher than in the contralateral LNs. Cy5.5-LyP-1 staining in LNs co-localized with LYVE-1, suggesting lymphatics-specific binding of LyP-1 peptide^[1].

LyP-1修飾負(fù)載核酸/藥物的靶向脂質(zhì)體

LyP-1修飾負(fù)載核酸/藥物的靶向脂質(zhì)體

系列產(chǎn)品（部分）

穿模肽TAT修飾負(fù)載核酸的靶向脂質(zhì)體

穿模肽R8修飾負(fù)載核酸的靶向脂質(zhì)體

腦腫瘤靶向肽RVG29修飾負(fù)載核酸的靶向脂質(zhì)體

靶向肽CRGD修飾負(fù)載核酸的靶向脂質(zhì)體

腦腫瘤靶向肽T7修飾負(fù)載核酸的靶向脂質(zhì)體

腫瘤淋巴管歸巢肽LyP-1修飾負(fù)載核酸/藥物的靶向脂質(zhì)體